Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
Aurora
13123 East 16th Ave Aurora, CO 80045

720-777-1234

Adam Green, MD

Pediatric Hematology / Oncology

Board Certified

Locations

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045

720-777-1234

Get directions

Provider Expertise

Clinical Interest for Patients

I help lead national clinical trials and give second opinions for other institutions for pediatric high-grade glioma, diffuse intrinsic pontine glioma (DIPG), and diffuse midline glioma. I also specialize in the diagnosis and management of other childhood tumors of the brain and spinal cord. In addition, I have expertise in other childhood cancers, benign blood disorders, and cell transplant.


Care Philosophy

I am committed to providing exceptional child- and family-centered care to my patients. I strive to communicate information truthfully to families at all times, and in an age-appropriate way to patients throughout childhood. As part of a team that includes physicians, nurse practitioners, nurses, social workers, and others, I aim to provide the highest quality, most innovative care to all patients from Colorado and beyond, to maximize cure rates and minimize adverse effects of treatment.


Specialties

  • Pediatric Hematology / Oncology ( 2015 )
  • Pediatrics ( 2010 )

Conditions & Treatments

  • Cancers

    Brain Cancer, Pediatric Cancer

  • Child and Teen Health

  • Brain and Nervous System

    Brain Tumors

Interests & Activities

Personal Interests

Spending time with my wife and three children, playing piano, singing, road cycling, running, tennis, and triathlon.


Volunteer Activities

I enjoy educating the community on childhood cancer research and advocating for our patients. I am also a volunteer youth soccer and baseball coach.


Education & Training

Medical Schools

MD, New York University School of Medicine (2006)


Undergraduate Schools

BA, Dartmouth College (NH) (2002)


Internships

University of Colorado (Children's Hospital Colorado) Program (2007)


Residency Program

University of Colorado (Children's Hospital Colorado) Program (2010)

University of Colorado (Children's Hospital Colorado) Program (2009)


Fellowships

Dana-Farber Cancer Institute/Boston Children’s Hospital/Harvard Medical School Program (2013)

Professional Memberships

Children's Oncology Group, Member, CNS Committee


University of Colorado Cancer Center, Mentored Member


Research & Grants

Grants

Career Development Award (K08) (2017)

Research Scholarship (2017)

Epidemiology Research Grant (2019)

Community Outreach Research Grant (2020)

Research Grant (2020)

Research Grant (2020)


Research Interests for Patients

My research focuses on a specific type of cancer called high-grade glioma, an aggressive brain tumor affecting both children and adults. We focus especially on two pediatric subtypes called diffuse intrinsic pontine glioma and pediatric glioblastoma. I work in the lab to find new treatments for these tumors; we then study the treatments in laboratory models of the tumors, including mouse models, and then bring the treatments most likely to be successful to clinical trials in children.

information for referring providers

Referral Contact Phone

720-777-1234

Clinical Interests for Referring Providers

I help lead national clinical trials and give second opinions for other institutions for pediatric high-grade glioma, diffuse intrinsic pontine glioma (DIPG), and diffuse midline glioma. I also specialize in the diagnosis and management of other childhood tumors of the brain and spinal cord. In addition, I have expertise in other childhood cancers, benign blood disorders, and cell transplant.

Research Interest for Referring Providers

My research focuses on novel targets and therapies for pediatric high-grade glioma, including diffuse intrinsic pontine glioma, and by extension, adult high-grade glioma as well. In my lab, we work to discover and exploit innovative, rational targets in these tumors, and to bring novel treatments against these targets through laboratory models of these diseases to early-phase clinical trials.